What is a stock summary page? Click here for an overview.
Business Description
Pieris Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US7207951036
Description
Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of the Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store, and transport a wide spectrum of molecules. The Company's clinical pipeline consists of immuno-oncology, or IO, bispecifics in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Geographically, all the operations of the firm function through the region of the United States.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.79 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -21.28 | |||||
| Beneish M-Score | 3.16 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -4.1 | |||||
| 3-Year EBITDA Growth Rate | 41.6 | |||||
| 3-Year EPS without NRI Growth Rate | 44.6 | |||||
| 3-Year FCF Growth Rate | 12.4 | |||||
| 3-Year Book Growth Rate | -21.3 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 13.7 | |||||
| 9-Day RSI | 22.36 | |||||
| 14-Day RSI | 28.14 | |||||
| 3-1 Month Momentum % | -3.42 | |||||
| 6-1 Month Momentum % | 61 | |||||
| 12-1 Month Momentum % | 43.75 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.82 | |||||
| Quick Ratio | 4.82 | |||||
| Cash Ratio | 4.55 | |||||
| Days Sales Outstanding | 287.09 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -20.9 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -1338.54 | |||||
| Net Margin % | -1179.96 | |||||
| FCF Margin % | -2069.97 | |||||
| ROE % | -69.84 | |||||
| ROA % | -46.07 | |||||
| ROIC % | -201.31 | |||||
| 3-Year ROIIC % | -56.21 | |||||
| ROC (Joel Greenblatt) % | -90.58 | |||||
| ROCE % | -79.23 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 12.43 | |||||
| PB Ratio | 1.1 | |||||
| Price-to-Tangible-Book | 1.1 | |||||
| EV-to-EBIT | 0.46 | |||||
| EV-to-EBITDA | 0.46 | |||||
| EV-to-Revenue | -6.22 | |||||
| EV-to-FCF | 0.3 | |||||
| Price-to-GF-Value | 5.27 | |||||
| Price-to-Net-Current-Asset-Value | 1.1 | |||||
| Price-to-Net-Cash | 1.19 | |||||
| Earnings Yield (Greenblatt) % | 217.39 | |||||
| FCF Yield % | -155.87 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:PIRS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Pieris Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1.352 | ||
| EPS (TTM) ($) | -12.17 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | -0.57 | ||
| 3-Year Sortino Ratio | -0.79 | ||
| Volatility % | 80.64 | ||
| 14-Day RSI | 28.14 | ||
| 14-Day ATR ($) | 0.799867 | ||
| 20-Day SMA ($) | 16.221575 | ||
| 12-1 Month Momentum % | 43.75 | ||
| 52-Week Range ($) | 6.2 - 22.32 | ||
| Shares Outstanding (Mil) | 1.32 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Pieris Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Pieris Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Pieris Pharmaceuticals Inc Frequently Asked Questions
What is Pieris Pharmaceuticals Inc(PIRS)'s stock price today?
The current price of PIRS is $13.60. The 52 week high of PIRS is $22.32 and 52 week low is $6.20.
When is next earnings date of Pieris Pharmaceuticals Inc(PIRS)?
The next earnings date of Pieris Pharmaceuticals Inc(PIRS) is 2025-05-15 Est..
Does Pieris Pharmaceuticals Inc(PIRS) pay dividends? If so, how much?
Pieris Pharmaceuticals Inc(PIRS) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers